Yahoo Finance1mon
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
in August 2024 – a facility focused on developing novel RNA-based and DNA-based medicine. MASH is a form of non-alcoholic liver disease, which describes a spectrum of conditions like steatosis ...
Medical Xpress24d
Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical ...
Business Wire1mon
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications. Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, ...
Nasdaq22d
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of ...